Benyo Tech Completes Series A3 Financing of Several Hundred Million RMB to Accelerate Intelligent Automation Transformation in Life Sciences

VCBeat has learned that recently, a company dedicated to accelerating the intelligent automation transformation in the life sciences sectorShanghai Bioyond Technology Co., Ltd. (hereinafter referred to as “BIOYOND Robotics”）, announced the successful completion of a Series A3 financing round amounting to hundreds of millions of yuan. This round of financing was led byPanlin CapitalLead Investor,Qiming Venture Partners, BioTrack CapitalContinued follow-on investment.

BIOYOND Robotics was established in March 2021, with its headquarters located in Shanghai Zhangjiang Science City, a global hub for technological innovation. Its founding team comprises elite professionals from Fortune 500 companies in the fields of robotics and life sciences. Leveraging profound scientific research expertise and a strong heritage of product innovation, BIOYOND is spearheading an intelligent automation revolution in the life sciences sector.

BIOYOND Robotics integrates cutting-edge robotics, high-precision visual recognition, and advanced artificial intelligence to deliver a suite of pioneering, user-friendly, and unattended intelligent automation products and solutions tailored for laboratories engaged in scientific research, clinical diagnostics, and physicochemical applications, thereby redefining industry standards.

Leveraging vast industry data and cutting-edge algorithmic models, BIOYOND Robotics has created “domain-cognitive and reasoning-capable” intelligent laboratory robots. These robots demonstrate exceptional decision-making and execution capabilities in complex and dynamic research environments, truly making automation accessible and unlocking the infinite potential of scientific innovation, thereby driving global laboratories toward higher levels of excellence.

Since its inception, BIOYOND Robotics has completed multiple rounds of financing totaling hundreds of millions of yuan. The funds raised have been primarily allocated to R&D, product development and manufacturing, and market expansion, thereby continuously addressing and meeting the urgent demand for intelligent automation products and solutions in the biopharmaceutical and other industries.

“Amidst the wave of intelligent automation transforming the life sciences industry, intelligent and automated technologies undoubtedly serve as the core driving force. At BIOYOND Robotics, we are committed to building a future where automation is accessible, unleashing scientific innovation and driving excellence in laboratory operations,” said Tang Yang, Founder and CEO of BIOYOND Robotics. “Through our intelligent automation products and solutions, we liberate scientists from extensive, simple, and repetitive tasks, enabling them to focus on higher-level research activities, thereby advancing specialized disciplines and expanding infinite possibilities for the future.”

Leveraging its leading robotics, automation, and artificial intelligence technologies, along with a profound understanding of life science scenarios, BIOYOND Robotics has continuously developed a general-purpose laboratory robotics platform—LabGenius Laboratory Robot, a one-stop laboratory software platform—LabMind Laboratory Software, and a compact intelligent laboratory application platform—LabMate Laboratory Assistant, to meet the intelligent automation needs of diverse scenarios.

Figure: BIOYOND Robotics’ New Family of Laboratory Automation Products

BIOYOND Robotics not only continues to innovate in the field of small-scale intelligent automation products, but also demonstrates profound professional expertise in large-scale customized intelligent automation projects. The company has successfully implemented coverage acrossDrug Screening, Synthetic Biology, Cell and Gene Therapy, Omics Research, Applied Chemistry, Clinical Diagnosticssuch as large-scale projects in many key areas, leveraging outstanding technical strength and efficient engineering delivery capabilities to continuously provide customers with leading intelligent laboratory automation solutions.

Figure: BIOYOND Robotics Intelligent Automation Solutions (Partial)

Currently, BIOYOND Robotics has expanded its business footprint to the United States, Europe, and other countries and regions. By establishing a multi-regional presence, the company has attracted numerous top-tier industry elites, further accelerating the implementation and deepening of its internationalization strategy. This enables BIOYOND to comprehensively introduce its cutting-edge technologies, innovative products, and exceptional services to the global market. Its solutions are widely applied across various sectors, including pharmaceuticals, materials science, agriculture, clinical settings, government agencies, universities, and research institutes, serving over a thousand clients. Looking ahead, with the continuous launch of standardized products and the ongoing expansion of application scenarios, the company’s technological prowess and product competitiveness are expected to gain further recognition.

Li Yuhui, Founding Managing Partner of Panlin Capitalstating: “Laboratory automation is at a juncture of ‘transforming the existing base’ and ‘explosive growth in new demand,’ with extensive downstream application scenarios. BIOYOND Robotics’ core team has deep expertise in robotics R&D, coupled with a strong background in life sciences. Building on a thorough understanding of automation needs, the company has developed an implementable technology platform and a mature, reliable product portfolio. Panlin Capital is firmly optimistic about the trend of deep integration between life sciences and automation, and looks forward to the company leveraging automation technologies to facilitate industrial upgrading in the life sciences sector.”

Dr. Kan Chen, Partner at Qiming Venture Partnersstated: “Since making our initial investment in BIOYOND Robotics in 2021, we have witnessed the company’s continuous progress and evolution in underlying technology and product development, business expansion, and team building. Throughout its growth, we have also observed substantial and diverse user demands. These factors have driven Qiming Venture Partners to make multiple follow-on investments in BIOYOND Robotics. We remain firmly optimistic about the laboratory automation sector and look forward to BIOYOND Robotics playing a pivotal role in driving a paradigm shift in the life sciences industry.”

Dr. Li Han, Executive Director of BioTrack Capital“Automation and intelligence are fundamentally transforming the life sciences industry, and BIOYOND Robotics’ product portfolio has become a powerful productivity tool that meets customers’ demands for high efficiency and standardization. BioTrack Capital believes that the company’s products and business logic are highly competitive in the market. Over the past year since its investment, BioTrack Capital has witnessed the team’s strong execution capabilities and commercialization prowess. By continuing to invest in this round, BioTrack Capital looks forward to seeing BIOYOND Robotics achieve outstanding results in both the domestic and international markets.”

Panlin Capital, established in 2010, adheres to the investment theme of “Technology Creates the Future, Innovation Leads Upgrading.” It focuses on two major sectors: healthcare and biotechnology, as well as To-B and technology. The firm specializes in identifying angel to Series A projects, committed to “finding entrepreneurs among scientists and empowering innovators among entrepreneurs.” In the healthcare and biotechnology sector, Panlin Capital invests in innovative drug development companies and innovative medical device manufacturers addressing the prevention, diagnosis, and treatment of major diseases with unmet clinical needs, while also seeking derivative investment opportunities in life sciences and biotechnology.

Qiming Venture Partners was established in 2006. Currently, Qiming Venture Partners manages 11 US dollar funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early-stage and growth-stage companies in the Technology and Consumer (T&C) and Healthcare sectors. To date, Qiming Venture Partners has invested in more than 530 high-growth innovative enterprises, among which over 200 have gone public on exchanges such as the New York Stock Exchange, NASDAQ, the Hong Kong Stock Exchange, the Shanghai Stock Exchange, and the Shenzhen Stock Exchange, or exited through mergers and acquisitions. Additionally, more than 70 of these portfolio companies have become industry-recognized unicorns or super unicorns.

BioTrack Capital, established in 2017, is a professional investment firm dedicated to investing in and incubating outstanding healthcare startups in the Chinese market. Currently, BioTrack Capital manages two RMB funds and two USD funds, with total assets under management approaching RMB 10 billion. More than just an investor, BioTrack Capital serves as a long-term partner to entrepreneurs. Since its inception, the firm has remained entrepreneur-centric, providing sustained support and active empowerment to exceptional founders in the healthcare sector, fostering an industry ecosystem, and cultivating the next generation of leading enterprises in China’s healthcare industry.

BIOYOND Robotics is headquartered in Zhangjiang Science City, Shanghai. Its founding team hails from Fortune 500 companies in the robotics and life sciences sectors, boasting profound scientific research expertise and exceptional product development capabilities.

BIOYOND Robotics is dedicated to accelerating the intelligent automation transformation of the life sciences industry. By leveraging cutting-edge robotics, computer vision, and artificial intelligence technologies, we provide more user-friendly and efficient products and solutions for various laboratories, including those engaged in scientific research, clinical diagnostics, and physicochemical applications. Building on extensive industry data and advanced algorithmic capabilities, BIOYOND Robotics has meticulously developed intelligent laboratory robots with “domain-specific cognitive and reasoning abilities.” Our mission is to make automation accessible, unleash scientific innovation, and drive excellence in laboratory development.

BIOYOND Robotics has established subsidiaries in Europe, the United States, and other countries and regions, bringing its products and solutions to the global market and serving over a thousand clients. Since its inception, the company has secured multiple rounds of strategic investments totaling hundreds of millions of yuan from top-tier investment institutions. It has been recognized as a National High-Tech Enterprise, a Shanghai “Specialized, Refined, Differential, and Innovative” SME, a Technology-Based SME, an Innovative SME, and a Benchmark Enterprise for Intelligent Robots in Shanghai.